ProKidney Corp (PROK) — Titan Protect Analysis

PROK

ProKidney Corp

Healthcare · ·

$1.80

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$539M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.10

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.7%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-49.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.75

+219% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 6 analysts covering this stock

About ProKidney Corp

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in

https://prokidney.com

Country: United States Employees: 231 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.494

Positive but modest risk-adjusted returns

Kelly Fraction

0.0823

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.340

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-29.2%

Historical annualised return based on price data

Max Drawdown

-86.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

162

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.75

Significantly more volatile than the market

52W High

$7.13

75% below the year high

52W Low

$0.54

233% above the year low

Avg Volume

924,490

Average daily shares traded — higher means easier to buy and sell

Short Ratio

23.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.53

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.44

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-19,881.9%

Profit from core operations before interest and tax

Free Cash Flow

$-78,626,872

Negative — the business is spending more than it generates

Revenue (TTM)

$889,000

Total revenue over the last 12 months

Net Income

$-72,289,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$5.75

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go